NASDAQ · COGT
Cogent Biosciences, Inc.
$31.96-$0.27 (-0.84%)
Cogent Biosciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.92% below the high.
Loading market information…
NYSE · AORT · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Artivion, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.42% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Artivion, Inc.’s forward annual dividend is $0.12 per share, paid quarterly. The forward yield is 0.51% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Artivion, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$0.06. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Artivion, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:41 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 |
|---|
| May 5, 2025 |
| -$0.01-108.33% vs estimate |
| $98.98M+4.38% vs estimate |
| Q4 2024 | Feb 24, 2025 | -$0.39-3,800.0% vs estimate | $97.31M-3.55% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | -$0.05-266.67% vs estimate | $95.78M+1.07% vs estimate |
|---|
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
12 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 3 contributors · Median target $40.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$31.96-$0.27 (-0.84%)
Cogent Biosciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.92% below the high.
$13.64+$0.25 (+1.83%)
LifeStance Health Group, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.11% below the high.
$126.52-$0.03 (-0.02%)
Integer Holdings Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.24% below the high.
$44.99-$0.73 (-1.6%)
Liquidia Corporation’s quoted price sits in the lower half of its reported 52-week range, 51.94% below the high.
$10.27+$0.29 (+2.91%)
Brookdale Senior Living Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.91% below the high.
$124.34+$2.16 (+1.77%)
Addus HomeCare Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.92% below the high.
$71.18+$0.21 (+0.3%)
Inspire Medical Systems, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.59% below the high.
$12.30+$0.37 (+3.1%)
Ardent Health Inc.’s quoted price sits in the upper half of its reported 52-week range, 18.49% below the high.
